EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSIPUG00000022110
Gene Symbol: GABRG3
3 Cross references
215 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSIPUG00000000932
Gene Symbol: GABBR1
4 Cross references
198 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSIPUG00000019420
Gene Symbol: GIPR
3 Cross references
185 Possible Orthologues:

Glucagon-Like Peptide 2 Receptor

Ensembl ID : ENSIPUG00000005364
Gene Symbol: LOC108273454
3 Cross references
205 Possible Orthologues:

Glucocorticoid Receptor

Ensembl ID : ENSIPUG00000010944
Gene Symbol: LOC108278798
3 Cross references
205 Possible Orthologues:

Glucokinase (Hexokinase 4)

Ensembl ID : ENSIPUG00000004068
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glucosidase, Beta, Acid

Ensembl ID : ENSIPUG00000008582
Gene Symbol: GBA
3 Cross references
253 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSIPUG00000001415
Gene Symbol: GRIN2A
4 Cross references
98 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSIPUG00000023830
Gene Symbol: GRIN2B
3 Cross references
261 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSIPUG00000012535
Gene Symbol: GRIN2C
3 Cross references
249 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSIPUG00000024907
Gene Symbol: GRIN3A
3 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSIPUG00000002663
Gene Symbol: GRIK1
4 Cross references
248 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).